




<b>Catalog Number</b>	GTX70174	Package: 100 µl	<a href="#">Reference</a> ( 88 )
<b>Product Name</b>	Estrogen Receptor beta antibody [14C8]		
<b>Full Name</b>	estrogen receptor 2 (ER beta)		
<b>Synonyms</b>	ESR-BETA, ESR2, 2100, ESRB, Q92731, ERBETA, 601663, ER-BETA, NR3A2, ER beta, ESRBETA, ESR BETA		
<b>Product Description</b>	Mouse monoclonal [14C8] antibody to estrogen receptor beta		
<b>Specificity</b>	Strong Erb staining in epithelial cell nuclei. Occasional weak to moderate staining is seen in surrounding stromal and endothelial cell nuclei. Sporadic light cytoplasmic staining is sometimes observed. We have also successfully detected ERb in colon and ovarian tumors using the same antibody.		
<b>Background</b>	The human ER-beta is a newly discovered estrogen receptor initially cloned and characterized from testis. The size and structure of ER-beta is very similar to ER-alpha with the ligand and DNA binding domains being highly conserved, while the amino terminus which serves as their transactivation domain has diverged significantly. Similar in function to ER-alpha ER-beta binds to estrogen with a high affinity and regulates estrogen specific gene activation through direct interaction with estrogen response elements (ERE's).		
<b>Host</b>	Mouse		
<b>Clonality</b>	Monoclonal		
<b>Clone Name</b>	14C8		
<b>Isotype</b>	IgG2b		
<b>Light Chain</b>	kappa		
<b>Target</b>	ER beta		
<b>Immunogen</b>	Amino acids 1-153 of human ER-beta expressed in E. coli.		
<b>Antigen Species</b>	Human		
<b>Species Reactivity</b>	Human, Mouse, Monkey		
<b>Applications</b>	FACS, ICC/IF, IHC, IHC-P, WB, ChIP assay		
<b>Application Note</b>	For IHC, a recommended protocol is provided. For WB: Use at a concentration of 1-5 µg/ml. For ChIP: Use at an dependent assay. Not tested in other applications. Optimal dilutions/concentrations should be determined by the researcher.		
<b>Positive Controls</b>	Recombinant fusion protein		
<b>Predicted Target Size</b>	58-60 kDa		
<b>Form Supplied</b>	Liquid		
<b>Purification</b>	Protein G Affinity Purified		
<b>Purification Note</b>	From ascitic fluid		
<b>Concentration</b>	1.23 mg/ml (Please refer to the vial label for the specific concentration)		
<b>Storage Buffer</b>	Phosphate-buffered saline, pH 7.4, containing no preservatives		
<b>Storage Instruction</b>	Keep as concentrated solution. Store at 4°C short term. For extended storage aliquot and store at -20°C or below. Avoid freeze-thaw cycles.		
<b>Notes</b>	For <i>In vitro</i> laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.		
<b>ResearchArea</b>	<a href="#">Cancer</a> > <a href="#">Apoptosis</a> > <a href="#">Metastasis and Invasion</a> > <a href="#">Invasion</a> <a href="#">Cancer</a> > <a href="#">Tumor biomarkers</a> <a href="#">Cancer</a> > <a href="#">Type of cancer</a> > <a href="#">Breast</a> > <a href="#">Ductal</a>		

## Application Reference


1. Maneix L (2015) *Proc Natl Acad Sci U S A* 5135-40
2. Bethea CL (2015) *J Chem Neuroanat* 19-27
3. Rajapaksa G (2014) *Oncogene*
4. Curioni-Fontecedro A (2014) *Cytology & Histology*
5. Yuan B (2014) *J Clin Invest*
6. Taniuchi S (2014) *Mol Cell Endocrinol* 00165-8
7. Hsieh TH (2014) *Carcinogenesis*
8. Ahn HY (2014) *Clin Endocrinol (Oxf)*
9. Velickovic K (2014) *J Clin Endocrinol Metab* 151-9
10. Savinov AY (2006) *Cancer Res* 2716-24
11. Scariano JK (2008) *J Recept Signal Transduct Res* 285-93
12. Zheng FF (2005) *Mol Cell Biol* 8273-84
13. Caiazza F (2007) *Biochem Biophys Res Commun* 102-7
14. Paruthiyil S (2004) *Cancer Res* 423-8
15. Honma N (2011) *Cancer Sci* 1848-54
16. Hopp TA (2004) *Clin Cancer Res* 7490-9
17. Thomas C (2012) *Breast Cancer Res* R148
18. Helguero LA (2005) *Oncogene* 6605-16
19. Al-Dhaheer MH (2007) *Mol Endocrinol* 439-56
20. Paruthiyil S (2009) *PLoS One* e6271
21. Jones LP (2005) *Oncogene* 3554-62
22. Khalaj AJ (2013) *Proc Natl Acad Sci U S A* 19125-30
23. Belcher SM (2009) *Endocrinology* 1112-21
24. Huang GS (2009) *Am J Obstet Gynecol* 457.e1-5
25. Chakravarty D (2010) *Acta Histochem* 355-63
26. Verma MK (2012) *Life Sci* 800-8
27. Bukulmez O (2008) *Endocrinology* 1190-204
28. Grubberger-Saal SK (2007) *Clin Cancer Res* 1987-94
29. Maehle BO (2009) *APMIS* 644-50
30. Verma MK (2013) *J Transl Med* 167
31. Madeira M (2013) *BMC Cancer* 425
32. Ohata C (2008) *J Dermatol* 215-21
33. Takagi K (2013) *Horm Cancer* 1-11
34. Zuguchi M (2012) *Cancer Sci* 1348-55
35. Vouk K (2011) *J Steroid Biochem Mol Biol* 231-42
36. Poola I (2005) *Endocrine* 227-38
37. Sase T (2012) *Int J Cancer* 2284-93
38. Verma MK (2012) *Expert Opin Ther Targets* S91-102
39. Sato R (2012) *Anticancer Res* 3069-75
40. Hata S (2013) *Cancer Med* 305-15
41. Matsuyama A (2010) *Pathol Int* 212-6
42. Kulakosky PC (2003) *Biotechniques* 334-8, 340-3
43. Srilatha B (2004) *Urology* 382-6
44. Koldzic-Zivanovic N (2004) *Mol Cell Endocrinol* 33-42
45. Soliz J (2005) *Respir Physiol Neurobiol* 111-22
46. Jones LP (2008) *Oncogene* 794-802
47. Vivar OI (2010) *J Biol Chem* 22059-66
48. Tee MK (2004) *Mol Biol Cell* 1262-72
49. Setlur SR (2008) *J Natl Cancer Inst* 815-25
50. Vivar OI (2010) *Endocrinology* 1662-7
51. Paruthiyil S (2011) *Breast Cancer Res Treat* 777-84
52. Cvoro A (2007) *Endocrinology* 538-47
53. Cvoro A (2006) *Mol Cell* 555-64
54. Skliris GP (2002) *J Pathol* 155-62
55. Omoto Y (2003) *Oncogene* 5011-20
56. Miki Y (2005) *Cancer Lett* 197-210
57. Miki Y (2009) *J Steroid Biochem Mol Biol* 281-9
58. Urbanska K (2009) *J Cell Physiol* 392-401
59. Galluzzo P (2007) *Endocr Relat Cancer* 153-67
60. Tonetti DA (2003) *J Steroid Biochem Mol Biol* 47-55
61. Chojamts B (2011) *Stem Cells* 1485-95
62. Samartzis N (2012) *Reprod Biol Endocrinol* 30
63. Abe K (2010) *Hum Pathol* 190-8
64. Wong MH (2009) *J Clin Pathol* 789-93
65. Mak P (2010) *Cancer Cell* 319-32
66. Dohi O (2008) *Cancer Sci* 518-23
67. Linja MJ (2003) *Prostate* 180-6
68. Speirs V (2004) *Lancet Oncol* 174-81
69. Karlsson C (2012) *APMIS* 451-8
70. Fuqua SA (2003) *Cancer Res* 2434-9
71. Li XQ (2003) *Pathol Int* 671-9
72. Miki Y (2011) *Mol Cell Endocrinol* 168-74
73. Raso MG (2009) *Clin Cancer Res* 5359-68
74. Dietrich W (2006) *J Soc Gynecol Investig* 512-7
75. Chakravarty D (2008) *Appl Immunohistochem Mol Morphol* 535-42
76. Ishibashi H (2005) *Cancer Res* 6450-8
77. Skliris GP (2006) *Br J Cancer* 616-26
78. Skliris GP (2007) *Breast Cancer Res Treat* 75-85
79. Huang GS (2010) *Am J Obstet Gynecol* 242.e1-5
80. Skliris GP (2003) *J Pathol* 213-20
81. Saji S (2002) *Cancer Res* 4849-53
82. Balfe P (2004) *Eur J Surg Oncol* 469-74
83. Mehasseb MK (2011) *Fertil Steril* 2228-35, 2235.e1
84. Navaratnam S (2012) *Horm Cancer* 93-100
85. Schwartz AG (2005) *Clin Cancer Res* 7280-7
86. Sato R (2009) *Cancer Res* 914-22
87. Poola I (2005) *Clin Cancer Res* 7579-85
88. Jeong H (2009) *Basic and Applied Pathology*. 118-24



B. Infiltrating lobular carcinoma of the breast.

**GTX70174 IHC Image**

B. Infiltrating lobular carcinoma of the breast.



**GTX70174 WB Image**

Non-transfected (-) and transfected (+) 293T whole cell extracts (30 µg) were separated by 7.5% SDS-PAGE, and the membrane was blotted with Estrogen Receptor beta antibody (GTX70174) diluted at 1:5000.